Revolutionising cancer care
As the Oncology Global Franchise, we are the strategic engine driving AstraZeneca's oncology ambition at a global scale.
We have a bold ambition to eliminate cancer as a cause of death. We aim to deliver innovative medicines across multiple scientific platforms and pioneer new technologies to detect and diagnose cancer earlier, personalise treatment, and optimise the care experience for all patients. We have a vision where cancer can be outsmarted and, in some cases, even cured. We are focusing our efforts on key tumour areas and developing a broad portfolio of personalised treatments that target different subtypes across all stages of disease.
Innovation alone won’t solve cancer – it takes extraordinary people working toward the same goal to achieve this collective purpose. Recognising this, we are accelerating our vision to transform care through partnerships across the healthcare ecosystem that improve access and delivery to improve patient care.
Inside the Oncology Global Franchise Business
Disrupt to redefine cancer treatment
We’re all here to make an impact – to achieve our bold ambition of eliminating cancer as a cause of death. In the Oncology Business Unit we relentlessly follow the science, challenging the status quo to deliver more effective treatments to patients in need. Our commitment means we purposefully push back the limits of knowledge to change the practice of medicine. To ensure no patient is left behind, no matter what stage of disease. In the Oncology Global Franchise, we operate as a unified global business, connecting commercial strategy with scientific innovation to accelerate impact at scale.
It’s our launch excellence and commercial effectiveness that will make the difference, empowering us to deliver the true value and potential of our life-changing medicines. Fuelled by partnerships, both internally and externally, we bring together diverse minds, knowledge and skills, sharing and working together, comfortable learning from failures. Here you’ll find varied opportunities, access to industry-leading research and technology, and product launches from a pipeline like no other.
Come and be a part of the team that makes it happen. Together we can make this the greatest decade ever in the fight against cancer.
What drives us at the Oncology Global Franchise
Your next role in the Oncology Global Franchise starts here
- Global Marketing Associate Director Breast Cancer Brand Management Gaithersburg, Maryland
- Global Marketing Associate Director, Lung Cancer Brand Management Gaithersburg, Maryland
- Global Commercial Director, Breast Cancer (ADCs) Brand Management Gaithersburg, Maryland
- Global Commercial Associate Director, Solid Tumor Franchise Brand Management Gaithersburg, Maryland
At AstraZeneca, our purpose is clear: ensure innovation reaches patients earlier, more precisely, and more equitably across every geography, tumor type, and health system.
Sunil Verma - SVP, Global Head, Oncology Franchise
Our tumour areas of focus
Our scientific approach is anchored in the ambition to address unmet patient needs to research and develop next-wave therapies with the greatest potential for patient impact. We are focusing our efforts on key tumour areas including lung, breast, gastrointestinal, gynaecological, genitourinary and haematology.
We are striving to make cures a reality for the millions of people across the world living with cancer every day.
Our people
We foster an inclusive and entrepreneurial culture where diversity drives innovation and progress, and where every voice is encouraged to speak up and drive change. Together, we are inspiring and supporting the next-generation of scientists, engineers and healthcare professionals to transform the patient experience in oncology.
We are building one of the fastest-growing, highest-performing oncology organisations in the industry
Our scientific platforms
Across our intentionally designed portfolio, we are harnessing a breadth of scientific platforms to attack cancer from multiple angles. Each platform is designed to leverage emerging technologies that deepen biological understanding and help to personalise treatment with the ambition to bring more patients the benefits of innovation.
Together, they form the foundation of our strategy to transform cancer care.
Our pipeline
We aim to revolutionise cancer care through our portfolio, our pipeline and our people. Through the relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry. We are balancing focus on our industry-leading pipeline with the active life-cycle management of our existing medicines.
We follow the science, wherever it takes us, in pursuit of the medicines that improve patient outcomes.
